Last reviewed · How we verify
Epidiolex — Competitive Intelligence Brief
marketed
Caspase-1
Neuroscience
Small molecule
Live · refreshed every 30 min
Target snapshot
Epidiolex (CANNABIDIOL) — Jazz Pharms Res. Epidiolex works by inhibiting the activity of caspase-1, a protein involved in the inflammatory response and neuronal excitability.
Comparator set (3 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Epidiolex TARGET | CANNABIDIOL | Jazz Pharms Res | marketed | Caspase-1 | 2018-01-01 | |
| Epidiolex | Epidiolex | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | marketed | N-arachidonyl glycine receptor, Cannabinoid receptor 2, Caspase-1 | ||
| ICE | ICE | MedImmune LLC | marketed | Caspase inhibitor | Caspase-1 (ICE) | |
| bIAP bolus and 8h infusion | bIAP bolus and 8h infusion | Alloksys Life Sciences B.V. | phase 3 | Caspase-1 inhibitor | Caspase-1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
Cite this brief
Drug Landscape (2026). Epidiolex — Competitive Intelligence Brief. https://druglandscape.com/ci/cannabidiol. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab